U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/64441 | https://www.ncbi.nlm.nih.gov/pubmed/64442

Dodecyl Ethyleneglycol Monoether (lauryl ethoxylate) is a nonionic compound, that used as environmentally friendly non-Ionic surfactant with marked antibacterial activity. Dodecyl Ethyleneglycol Monoether is effective permeation enhancer, both for the passive process as well as for samples subjected to iontophoresis.

Originator

Curator's Comment:: Polidocanol was synthesized by German chemical/pharmaceutical company BASF and introduced in 1936 as a local and topical anesthetic under the tradename Sch 600. Additional resources: http://www.lovelylegs.com/treatments/sclerotherapy/history/ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787977/

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ASCLERA

Approved Use

Asclera® (polidocanol) is indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. Asclera has not been studied in varicose veins more than 3 mm in diameter. Asclera (polidocanol) is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It has not been studied in larger varicose veins > 3 mm in diameter. (1)

Launch Date

1.26990719E12
Curative
ASCLERA

Approved Use

Asclera® (polidocanol) is indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. Asclera has not been studied in varicose veins more than 3 mm in diameter. Asclera (polidocanol) is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It has not been studied in larger varicose veins > 3 mm in diameter. (1)

Launch Date

1.26990719E12
Primary
Varithena

Approved Use

Varithena™ (polidocanol injectable foam) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena™ improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.

Launch Date

1.33894085E12
Primary
Varithena

Approved Use

Varithena™ (polidocanol injectable foam) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena™ improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.

Launch Date

1.33894085E12
PubMed

PubMed

TitleDatePubMed
Local therapeutic injection in bleeding peptic ulcer: a comparison of adrenaline to adrenaline plus a sclerosing agent.
2002 Jul
[Local sclerosing treatment with etoxiesclerol in ORL disease: Rendu-Osler disease, granuloma, angioma...].
2002 Nov
Specific accumulation and growth inhibitory effects of hybrid liposomes to hepatoma cells in vitro.
2002 Nov 18
The effects of water-soluble cyclodextrins on the histological integrity of the rat nasal mucosa.
2002 Oct 10
A new therapeutic approach for treatment of hydatid cysts of the spleen.
2002 Sep
Evaluation of bioadhesive properties of excipients containing lipophilic adjuvants.
2003
The efficacy of polidocanol in pleurodesis in rats.
2003
Long term results of compression sclerotherapy.
2003
Pretreatment with a water-based surfactant formulation affects transdermal iontophoretic delivery of R-apomorphine in vitro.
2003 Apr
Venous lake of the lip treated with a sclerosing agent: report of two cases.
2003 Apr
An unusual complication of facial sclerotherapy.
2003 Apr
Endoscopic obliteration of a recurrent tracheoesophageal fistula with enbucrilate and polidocanol in a child.
2003 Apr
The multidrug resistance protein ABCC1 drug-binding domains show selective sensitivity to mild detergents.
2003 Apr 18
Solubilization of adenylyl cyclase from human myometrium in a alphas-coupled form.
2003 Aug
Endoscopic sclerotherapy compared with no specific treatment for the primary prevention of bleeding from esophageal varices. A randomized controlled multicentre trial [ISRCTN03215899].
2003 Aug 15
Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results.
2003 Dec
Influence of nonionic surfactants on the chromatographic behaviour of proteins in hydrophobic interaction chromatography.
2003 Dec
[The place of endoscopic treatment in hemorrhagic ulcers].
2003 Feb 8
Short- and medium-term clinical efficacy of three endoscopic therapies for achalasia: a single-blinded prospective study.
2003 Jan
Purification and characterization of catalytic domains of gelatinase A with or without fibronectin insert for high-throughput inhibitor screening.
2003 Jan
[Endoscopic therapy for esophageal and gastric varices].
2003 Jan 10
[Favorable results with duplex-guided compression sclerotherapy for varices of the small saphenous vein; a retrospective study].
2003 Jan 18
[Sclerotherapy of female varicocele].
2003 Jan-Feb
Membrane cholesterol regulates LFA-1 function and lipid raft heterogeneity.
2003 Jul 1
Phlebography: why it is important to study radiological imaging of spermatic veins.
2003 Mar
From clinical evidence to everyday practice: implementing findings from a cost-effectiveness analysis for endoscopic injection therapy for upper-gastrointestinal bleeding.
2003 Mar
Treatment of venous malformations with sclerosant in microfoam form.
2003 Nov
Clinical evaluation of combined endoscopic variceal ligation and sclerotherapy of gastric varices in liver cirrhosis.
2003 Nov
Sclerotherapy treatment of telangiectasias and varicose veins.
2003 Sep
Sclerosing therapy in chronic Achilles tendon insertional pain-results of a pilot study.
2003 Sep
Investigation of the phase behavior and an evaporation study of systems of lavender oil, water, Laureth 4, and Tween 80.
2003 Sep-Oct
Comparison of argon plasma coagulation and paravariceal injection sclerotherapy with 1% polidocanol in mucosa-fibrosing therapy for esophageal varices.
2004
[Sclerotherapy of small pelvis varicosis].
2004
[Sclerosing treatment of vascular malformations].
2004
Comparison and sequential study of long pulsed Nd:YAG 1,064 nm laser and sclerotherapy in leg telangiectasias treatment.
2004
The time-dependent distribution of phosphorylated intermediates in native sarcoplasmic reticulum Ca2+-ATPase from skeletal muscle is not compatible with a linear kinetic model.
2004 Apr 13
Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms.
2004 Feb 1
Effect of cutaneously applied nonionic surfactants and local anesthetic bases on thermal sensations.
2004 Jan
Treatment of subcutaneous dialysate leak with polidocanol: case report.
2004 Jan-Feb
Argon plasma coagulation versus injection sclerotherapy in peptic ulcer hemorrhage--a prospective, controlled study.
2004 Jan-Feb
A randomized study of the safety of outpatient care for patients with bleeding peptic ulcer treated by endoscopic injection.
2004 Jul
Chronic tendon pain--implications for treatment: an update.
2004 Jul
Effect of membrane perturbants on the activity and phase distribution of inositol phosphorylceramide synthase; development of a novel assay.
2004 Jul 6
Ultrasound-guided injection of polidocanol microfoam in the management of venous leg ulcers.
2004 Jun
Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins.
2004 Mar
Nitric oxide transfer from the NO-donor S-nitroso-N-acetylpenicillamine to monomers and dimers of water-soluble iron-porphyrins.
2004 Mar
Efficacy of endoscopic clipping for actively bleeding peptic ulcer: comparison with polidocanol injection therapy.
2004 Mar-Apr
[An elderly case of acute myelocytic leukemia complicated with bleeding gastric angiodysplasia, successfully treated with topical endoscopic polidocanol injection].
2004 May
Perforans varicosis: treatment of the incompetent perforating vein is important.
2004 May
Efficacy of sclerotherapy in varicose veins-- prospective, blinded, placebo-controlled study.
2004 May
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Varithena (Polidocanol): Repeat treatment may be necessary if the size and extent of the veins to be treated require more than 15 mL of Varithena. Separate treatment sessions by a minimum of 5 days. (http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205098s005lbledt.pdf) Asclera (Polidocanol): Repeat treatments may be necessary if the extent of the varicose veins requires more than 10 ml. These treatments should be separated by 1 to 2 weeks. (http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021201lbl.pdf)
Varithena (Polidocanol): Up to 5 mL per injection and no more than 15 mL per session Asclera (Polidocanol): 0.1 to 0.3 mL per injection and no more than 10 mL per session.
Route of Administration: Intravenous
Human great saphenous vein in vitro model. Median endothelial cell loss with 3% polidocanol was 63.5% (62.2–82.8) at 5 min. of polidocanol exposure and 85.9% (83.8–92.5) at 15 min.
Name Type Language
POLIDOCANOL
JAN   MI   ORANGE BOOK   VANDF   WHO-DD  
Common Name English
LAUROMACROGOL 450
Common Name English
LAUROMACROGOL [JAN]
Common Name English
LAUROMACROGOL 400
EP   INN   MART.  
INN  
Official Name English
LAURETH 9 [USAN]
Common Name English
AETHOXY-SKLEROL
Common Name English
POLYETHYLENE GLYCOL 450 LAURYL ETHER
Common Name English
10XBIO
Common Name English
NONAETHYLENE GLYCOL MONODODECYL ETHER
Common Name English
PEG-9 LAURYL ETHER
Common Name English
10XB-101
Common Name English
MARLIPAL 24/90
Brand Name English
VARITHENA
Brand Name English
LAUROMACROGOL 400 [MART.]
Common Name English
LAURETH-9 [INCI]
Common Name English
NIKKOL BL-9EX
Brand Name English
POLIDOCANOL [VANDF]
Common Name English
POLYOXYL 9 LAURYL ETHER [USP-RS]
Common Name English
LAURETH 9
USAN  
USAN  
Official Name English
POLIDOCANOL [MI]
Common Name English
POLYETHYLENE GLYCOL MONOLAURYL ETHER (N=9)
Common Name English
POLYOXYL 9 LAURYL ETHER
Common Name English
LAUROMACROGOL 400 [INN]
Common Name English
MACROGOL 9 LAURYL ETHER
Common Name English
POLIDOCANOL [WHO-DD]
Common Name English
POLIDOCANOL [ORANGE BOOK]
Common Name English
POLIDOCANOL [JAN]
Common Name English
NONAOXYETHYLENE MONODODECYL ETHER
Common Name English
LAUROMACROGOL 400 [EP MONOGRAPH]
Common Name English
LAURETH-9
INCI  
INCI  
Official Name English
Classification Tree Code System Code
NDF-RT N0000175814
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
WHO-VATC QC05BB02
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
WHO-ATC C05BB02
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
FDA ORPHAN DRUG 464614
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL2108373
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
PRIMARY
DRUG BANK
DB06811
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
PRIMARY
EVMPD
SUB77418
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
PRIMARY
EVMPD
SUB02871MIG
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
PRIMARY
USP_CATALOG
1372435
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
PRIMARY USP-RS
MESH
C008976
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
PRIMARY
CAS
9002-92-0
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
GENERIC (FAMILY)
WIKIPEDIA
POLIDOCANOL
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
PRIMARY
INN
1562
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
PRIMARY
ECHA (EC/EINECS)
221-284-4
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
PRIMARY
ChEMBL
CHEMBL2109050
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
PRIMARY
FDA UNII
0AWH8BFG9A
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
PRIMARY
DRUG CENTRAL
4614
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
PRIMARY
CAS
3055-99-0
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
ALTERNATIVE
MERCK INDEX
M8945
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
PRIMARY Merck Index
EPA CompTox
3055-99-0
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
PRIMARY
ChEMBL
CHEMBL1231723
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
PRIMARY
RXCUI
968170
Created by admin on Fri Jun 25 21:18:29 UTC 2021 , Edited by admin on Fri Jun 25 21:18:29 UTC 2021
PRIMARY
Display Structure of POLIDOCANOL